Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [18]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 23959-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- BCL3 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated BCL3 antibody (Cat. #23959-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IF, IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references BCL3 drives an immunosuppressive tumor microenvironment in esophageal cancer by promoting M2 macrophage polarization via STAT3 activation.
Liver-specific Bcl3 Knockout Alleviates Acetaminophen-induced Liver Injury by Activating Nrf2 Pathway in Male Mice.
A Critical Role of DC-SIGN(+) Tumor-Associated Macrophages in Colorectal Cancer Immune Evasion and Progression via BCL-3-Mediated PD-L1 Expression.
Direct-in-NOD genetic ablation of Bcl3 leads to complete type 1 diabetes protection.
Dynamic changes in chromatin accessibility within one month of mouse intracerebral hemorrhage.
Immune checkpoint protein PD-L1 promotes transcription of angiogenic and oncogenic proteins IL-8, Bcl3, and STAT1 in ovarian cancer cells.
BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases.
Atypical IκB Bcl3 enhances the generation of the NF-κB p52 homodimer.
Divergent transcriptional regulation of astrocyte reactivity across disorders.
BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination.
SPaRTAN, a computational framework for linking cell-surface receptors to transcriptional regulators.
The Discovery of a Novel Antimetastatic Bcl3 Inhibitor.
The enhancer rare germline variation rs548071605 contributes to lung cancer development.
Bcl-3 promotes multi-modal tumour cell migration via NF-κB1 mediated regulation of Cdc42.
BCL‑3 promotes cyclooxygenase‑2/prostaglandin E2 signalling in colorectal cancer.
BCL-3 promotes a cancer stem cell phenotype by enhancing β-catenin signalling in colorectal tumour cells.
The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
A four-gene signature predicts survival in clear-cell renal-cell carcinoma.
Geng Y, Ma H, Liu M, Feng T, Lv Y, Li Z, Ma S, Wang H, Niu Y
Immunobiology 2026 Mar;231(2):153164
Immunobiology 2026 Mar;231(2):153164
Liver-specific Bcl3 Knockout Alleviates Acetaminophen-induced Liver Injury by Activating Nrf2 Pathway in Male Mice.
Gao J, Lu W, Xin Y, Ma H, Sheng X, Gao G, Kang X, Jiang S, Zhao Y, Lv Y, Niu Y, Liang Y, Wang H
Cellular and molecular gastroenterology and hepatology 2025;19(6):101483
Cellular and molecular gastroenterology and hepatology 2025;19(6):101483
A Critical Role of DC-SIGN(+) Tumor-Associated Macrophages in Colorectal Cancer Immune Evasion and Progression via BCL-3-Mediated PD-L1 Expression.
Zhang J, Zhao Y, Wang X, Miao C, Xu W, Wan C, Hu B, Qian F
ImmunoTargets and therapy 2025;14:1395-1410
ImmunoTargets and therapy 2025;14:1395-1410
Direct-in-NOD genetic ablation of Bcl3 leads to complete type 1 diabetes protection.
Racine JJ, Dwyer JR, Chapman HD, Bell A, Robledo RF, Serreze DV
Journal of immunology (Baltimore, Md. : 1950) 2025 Nov 1;214(11):2847-2860
Journal of immunology (Baltimore, Md. : 1950) 2025 Nov 1;214(11):2847-2860
Dynamic changes in chromatin accessibility within one month of mouse intracerebral hemorrhage.
Xiang R, OuYang K, Wang J, Chen Z, Tao J, Zhang X, Zhang H, Li Z, Wang L, Ding R, Liu C, Xie J, Hou Y, Wang J, Liu L, Wang M
iScience 2025 Jul 18;28(7):112815
iScience 2025 Jul 18;28(7):112815
Immune checkpoint protein PD-L1 promotes transcription of angiogenic and oncogenic proteins IL-8, Bcl3, and STAT1 in ovarian cancer cells.
Reddy SU, Sham R, Smith K, Gaire B, Vancura A, Vancurova I
The Journal of biological chemistry 2025 Apr;301(4):108339
The Journal of biological chemistry 2025 Apr;301(4):108339
BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases.
Carbo-Meix A, Guijarro F, Wang L, Grau M, Royo R, Frigola G, Playa-Albinyana H, Buhler MM, Clot G, Duran-Ferrer M, Lu J, Granada I, Baptista MJ, Navarro JT, Espinet B, Puiggros A, Tapia G, Bandiera L, De Canal G, Bonoldi E, Climent F, Ribera-Cortada I, Fernandez-Caballero M, De la Banda E, Do Nascimento J, Pineda A, Vela D, Rozman M, Aymerich M, Syrykh C, Brousset P, Perera M, Yanez L, Ortin JX, Tuset E, Zenz T, Cook JR, Swerdlow SH, Martin-Subero JI, Colomer D, Matutes E, Bea S, Costa D, Nadeu F, Campo E
Haematologica 2024 Feb 1;109(2):493-508
Haematologica 2024 Feb 1;109(2):493-508
Atypical IκB Bcl3 enhances the generation of the NF-κB p52 homodimer.
Pan W, Deng L, Wang H, Wang VY
Frontiers in cell and developmental biology 2022;10:930619
Frontiers in cell and developmental biology 2022;10:930619
Divergent transcriptional regulation of astrocyte reactivity across disorders.
Burda JE, O'Shea TM, Ao Y, Suresh KB, Wang S, Bernstein AM, Chandra A, Deverasetty S, Kawaguchi R, Kim JH, McCallum S, Rogers A, Wahane S, Sofroniew MV
Nature 2022 Jun;606(7914):557-564
Nature 2022 Jun;606(7914):557-564
BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination.
Parker C, Chambers AC, Flanagan DJ, Ho JWY, Collard TJ, Ngo G, Baird DM, Timms P, Morgan RG, Sansom OJ, Williams AC
DNA repair 2022 Jul;115:103331
DNA repair 2022 Jul;115:103331
SPaRTAN, a computational framework for linking cell-surface receptors to transcriptional regulators.
Ma X, Somasundaram A, Qi Z, Hartman DJ, Singh H, Osmanbeyoglu HU
Nucleic acids research 2021 Sep 27;49(17):9633-9647
Nucleic acids research 2021 Sep 27;49(17):9633-9647
The Discovery of a Novel Antimetastatic Bcl3 Inhibitor.
Soukupová J, Bordoni C, Turnham DJ, Yang WW, Seaton G, Gruca A, French R, Lee KY, Varnava A, Piggott L, Clarkson RWE, Westwell AD, Brancale A
Molecular cancer therapeutics 2021 May;20(5):775-786
Molecular cancer therapeutics 2021 May;20(5):775-786
The enhancer rare germline variation rs548071605 contributes to lung cancer development.
Wang X, Cheng H, Yang Y, Zuo X, Shao L, Yu D, Yang N, Zhang Y, Li R, Wang X, Shen B, Wang J, Shi X, Cao P, Sun L, Han X, Sun Y
Human mutation 2021 Dec 2;
Human mutation 2021 Dec 2;
Bcl-3 promotes multi-modal tumour cell migration via NF-κB1 mediated regulation of Cdc42.
Turnham DJ, Yang WW, Davies J, Varnava A, Ridley AJ, Conlan RS, Clarkson RWE
Carcinogenesis 2020 Oct 15;41(10):1432-1443
Carcinogenesis 2020 Oct 15;41(10):1432-1443
BCL‑3 promotes cyclooxygenase‑2/prostaglandin E2 signalling in colorectal cancer.
Collard TJ, Fallatah HM, Greenhough A, Paraskeva C, Williams AC
International journal of oncology 2020 May;56(5):1304-1313
International journal of oncology 2020 May;56(5):1304-1313
BCL-3 promotes a cancer stem cell phenotype by enhancing β-catenin signalling in colorectal tumour cells.
Legge DN, Shephard AP, Collard TJ, Greenhough A, Chambers AC, Clarkson RW, Paraskeva C, Williams AC
Disease models & mechanisms 2019 Mar 4;12(3)
Disease models & mechanisms 2019 Mar 4;12(3)
The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
Zou Y, Uddin MM, Padmanabhan S, Zhu Y, Bu P, Vancura A, Vancurova I
The Journal of biological chemistry 2018 Oct 5;293(40):15483-15496
The Journal of biological chemistry 2018 Oct 5;293(40):15483-15496
A four-gene signature predicts survival in clear-cell renal-cell carcinoma.
Dai J, Lu Y, Wang J, Yang L, Han Y, Wang Y, Yan D, Ruan Q, Wang S
Oncotarget 2016 Dec 13;7(50):82712-82726
Oncotarget 2016 Dec 13;7(50):82712-82726
No comments: Submit comment
Supportive validation
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The BCL3 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human BCL3. This antibody recognizes human antigen. The BCL3 antibody has been validated for the following applications: ELISA, WB analysis.
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HEK-293 cells were subjected to SDS PAGE followed by western blot with 23959-1-AP( BCL3 Antibody) at dilution of 1:300
- Other comments
- WB
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemistry of paraffin-embedded human lymphoma tissue slide using 23959-1-AP( BCL3 Antibody) at dilution of 1:50 (under 10x lens)
- Other comments
- IHC
